Third Medical Department for Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria.
Anticancer Res. 2011 Oct;31(10):3273-8.
BACKGROUND/AIM: Oncostatin M (OSM) and interleukin-6 (IL-6) are growth factors for prostate cancer (PC). Vascular endothelial growth factor (VEGF) and urokinase-type plasminogen-activator (u-PA) have been implicated in tumour progression. A possible interaction between IL-6, OSM, u-PA and VEGF in PC was investigated.
Primary prostate epithelial cells (PPEC) and DU-145 PC cells were treated with IL-6 or OSM and the effects on u-PA and VEGF expression were studied. Plasma levels of IL-6, OSM, u-PA and VEGF were determined in patients with or without PC.
In DU-145 cells, OSM and IL-6 up-regulated u-PA and VEGF significantly. Higher levels of IL-6 and OSM in metastasising PC than in nonmetastasising PC and benign prostatic hyperplasia (BPH) and correlations between IL-6, OSM, u-PA and VEGF were found.
OSM and IL-6 increase u-PA and VEGF in DU-145 cells but not in PPEC and possibly, by promoting matrix degradation and angiogenesis, could play a role in the pathogenesis of prostate cancer.
背景/目的： 肿瘤坏死因子 M（OSM）和白细胞介素 6（IL-6）是前列腺癌（PC）的生长因子。血管内皮生长因子（VEGF）和尿激酶型纤溶酶原激活剂（u-PA）已被牵连到肿瘤进展中。本研究旨在调查 IL-6、OSM、u-PA 和 VEGF 之间在 PC 中可能的相互作用。
用 IL-6 或 OSM 处理原代前列腺上皮细胞（PPEC）和 DU-145 PC 细胞，并研究其对 u-PA 和 VEGF 表达的影响。测定有或无 PC 的患者的血浆中 IL-6、OSM、u-PA 和 VEGF 水平。
在 DU-145 细胞中，OSM 和 IL-6 显著上调 u-PA 和 VEGF。转移性 PC 患者的 IL-6 和 OSM 水平高于非转移性 PC 和良性前列腺增生（BPH）患者，并且发现了 IL-6、OSM、u-PA 和 VEGF 之间的相关性。
OSM 和 IL-6 增加了 DU-145 细胞中的 u-PA 和 VEGF，但不会增加 PPEC 中的 u-PA 和 VEGF，可能通过促进基质降解和血管生成，在前列腺癌的发病机制中发挥作用。
